Exelixis
Open
$45.14
Prev. Close
$45.15
High
$45.20
Low
$45.12
Market Snapshot
$11.98B
15.3
1.80
$2.17B
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,077 full-time employees. The company went IPO on 2000-04-11. The firm has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. The company is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
emptyResult
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,077 full-time employees. The company went IPO on 2000-04-11. The firm has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. The company is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Recently from Cashu
Divergent Analyst Views on Exelixis Amidst Biopharmaceutical Competition and Market Challenges
Exelixis Faces Divergent Analyst Perspectives Amidst Competitive Biopharmaceutical Landscape Exelixis, a prominent player in the biopharmaceutical sector, has recently attracted significant attention…
Analysts Assess Exelixis's Future Amidst Biopharma Challenges and Opportunities
Evolving Perspectives on Exelixis's Future in Biopharma In recent months, Exelixis Inc. receives heightened attention from a diverse group of analysts, each offering unique insights into the company's…
Exelixis Enhances Oncology Strategy Amid Promising Developments with Pelareorep in Cancer Treatment
Exelixis' Strategic Position in Oncology Advances with Promising Insights into Pelareorep Exelixis, a prominent player in the oncology sector, remains keenly attuned to the evolving landscape of cance…
Oncolytics Biotech Advances Cancer Treatment Prospects with Promising Pelareorep Data
Oncolytics Biotech Poised for Breakthrough in Oncology Treatments Oncolytics Biotech Inc. makes significant strides in the oncology sector with focused efforts on its registrational programs for anal…